Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $1563 | $04 | $04 | $05 | $06 | $06 |
| Research and development | $13.2K3 | $03 | ||||
| Selling, general and admin | $219.3K3 | $75.4K4 | $74.0K7 | $75.4K5 | $59.9K6 | $12.7K8 |
| Operating expenses | ||||||
| Operating income | -$358.7K3 | -$138.8K4 | -$165.2K7 | -$235.9K5 | -$201.7K6 | -$60.6K8 |
| Interest | $123.9K3 | $196.1K4 | $245.4K7 | $232.2K5 | $198.2K6 | $216.7K8 |
| Income before tax | ||||||
| Income tax | $03 | $04 | $04 | $05 | $06 | $06 |
| Net income | -$467.8K3 | -$398.0K4 | $869.1K7 | -$736.9K5 | -$621.9K6 | -$252.7K8 |
| Fiscal year | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|---|---|
| Cash | $61.1K4 | $6917 | $460.1K5 | $322.0K6 | $130.4K6 | $55.4K8 |
| Current assets | $137.5K3 | $28.8K4 | $890.8K7 | $359.8K5 | $137.4K6 | $55.4K8 |
| Total assets | $358.5K3 | $212.6K4 | $1.4M7 | $581.8K5 | $137.4K6 | $55.4K8 |
| Accounts payable | ||||||
| Current liabilities | $1.8M3 | $1.9M4 | $2.1M7 | $2.1M5 | $2.3M5 | |
| Long-term debt | $1.5M6 | |||||
| Total liabilities | $1.8M3 | $1.9M4 | $2.1M7 | $2.1M5 | $2.3M6 | $2.4M8 |
| Retained earnings | ||||||
| Shareholders’ equity | -$1.4M4 | -$1.6M7 | -$749.6K5 | -$1.5M6 | -$2.1M8 | -$2.4M8 |
| Shares outstanding | 69.8M shares3 | 78.7M shares4 | 78.7M shares7 | 78.7M shares5 | 78.7M shares6 | 78.7M shares8 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
What it owns
What QUANTRX BIOMEDICAL CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Investments
Leadership
Who has led QUANTRX BIOMEDICAL CORP, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerWalter W. Witoshkin Oct 23, 2007 to Aug 5, 200912
- ChairWalter W. Witoshkin Oct 23, 2007 to Aug 5, 200912
- Chief financial officerSasha Afanassiev Aug 8, 2006 to Aug 5, 200913
Board members and other officers (9)
- OfficerSasha Afanassiev Mar 4, 2008 to Jan 30, 200914
- SecretaryWilliam H. Fleming Jul 27, 2006 to Aug 5, 200915
- V.P. of DiagnosticsCindy Horton Aug 8, 2006 to Mar 4, 200816
- Board memberMichael S. Abrams Mar 1, 2012 to Mar 1, 201217
- Board memberPatrick T. Mooney May 7, 2010 to May 7, 201018
- Board memberRobert G. Pinco May 7, 2010 to May 7, 201019
- Board memberShalom Hirschman Mar 20, 2007 to Sep 27, 201220
- Board memberEvan Levine Apr 18, 2006 to Feb 9, 200721
- Board memberWilliam H. Fleming Jul 27, 2006 to Aug 20, 201215
Former names
Timeline
Filings
10 filings to the SEC since October 2021: 1 annual reports, 4 quarterly reports, 1 major events, 4 other. The latest 10:
- Apr 9, 2025REVOKED EDGAR
- Nov 14, 202210-Q EDGAR
- Aug 24, 20228-K EDGAR
- Aug 22, 202210-Q EDGAR
- Aug 16, 2022NT 10-Q EDGAR
- May 16, 202210-Q EDGAR
- Apr 15, 202210-K EDGAR
- Mar 31, 2022NT 10-K EDGAR
- Nov 16, 202110-Q EDGAR
- Nov 15, 2021NT 10-Q EDGAR
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How QUANTRX BIOMEDICAL CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARQUANTRX BIOMEDICAL CORP1
- CIK0000820608
- Employer ID (EIN)33-02025741
- Filer statusNon-accelerated filer<br>smaller reporting company1
- Incorporated inNevada1
- Fiscal year endsDecember 311
- Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business addressP.O. Box 4960, Tualatin, OR 970621
- Phone267-880-15951
- Shares outstanding78,696,461 as of Nov 14, 202211
- Public float$1.0M as of Jun 30, 20218
- On EDGAR sinceAug 14, 19951
- Filings366 in all: 10-Q (47), 8-K (41), NT 10-Q (31), 10QSB (28), 4 (28), 424B3 (21), UPLOAD (17), NT 10-K (16)1
All 39 form types
10-K (15), 3 (14), CORRESP (12), SC 13D/A (9), SC 13D (7), 10-K/A (6), 10-Q/A (6), 10KSB (6), DEF 14A (6), 8-K/A (5), POS AM (5), S-2/A (5), SC 13G/A (5), 10KSB40 (4), PRE 14A (4), REGDEX (4), 10KSB/A (3), 10QSB/A (3), SC 13G (3), 3/A (2), 425 (2), S-2 (2), 10KSB40/A (1), 4/A (1), D (1), EFFECT (1), NT 10-Q/A (1), REVOKED (1), S-8 (1), SB-2 (1), SB-2/A (1)
- Latest filingsAnnual report (10-K) Apr 15, 2022
Quarterly report (10-Q) Nov 14, 2022
Proxy statement (DEF 14A) Nov 5, 2009
Latest 8-K (8-K) Aug 24, 2022
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARSasha Afanassiev, Officer
- 15SEC EDGARWilliam H. Fleming, Secretary
- 16SEC EDGARCindy Horton, V.P. of Diagnostics
- 17SEC EDGARMichael S. Abrams, Board member
- 18SEC EDGARPatrick T. Mooney, Board member
- 19SEC EDGARRobert G. Pinco, Board member
- 20SEC EDGARShalom Hirschman, Board member
- 21SEC EDGAREvan Levine, Board member
- 22SEC EDGARExecutive or director change